Skip to main content

Nagendran Sukumar

In the past year, 5 open-market sale filings worth $5.33M and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$5.33M
5 filings
Net
−$5.33M
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Nagendran Sukumar as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

TSHA Taysha Gene Therapies, Inc.

President and Head of R&D9 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 10, 2026 (view filing)6:54 PM ETJul 10Same dayNagendran SukumarPresident and Head of R&DSSale−200.0K$6.24−$1.25M−17.6%936.4K after10b5-1
Apr 13, 2026 (view filing)Apr 103 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$4.46−$892.0K−15.0%1.14M after10b5-1
Jan 27, 2026 (view filing)Jan 23-264 daysNagendran SukumarPresident and Head of R&DSSale−116.0K$4.72−$547.5K−8.1%1.32M after2 lots
Jan 14, 2026 (view filing)Jan 122 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$4.71−$942.0K−16.6%1.01M after10b5-1
Dec 1, 2025 (view filing)Nov 28-Dec 13 daysNagendran SukumarPresident and Head of R&DSSale−370.2K$4.58−$1.70M−26.9%1.01M after2 lots
Sep 12, 2025 (view filing)Sep 102 daysNagendran SukumarPresident and Head of R&DSSale−200.0K$3.23−$646.0K−16.6%1.01M after10b5-1
Aug 22, 2025 (view filing)Aug 211 dayNagendran SukumarPresident and Head of R&DSSale−57.1K$2.85−$162.6K−4.7%1.17M after
May 18, 2023 (view filing)May 162 daysNagendran SukumarPresident and Head of R&DPPurchase+5.00K$0.68+$3.40K+17.1%34.2K after
Feb 3, 2022 (view filing)Feb 21 dayNagendran SukumarDirectorPPurchase+10.0K$8.01+$80.1K+52.0%29.2K after